US doctors write billions of prescriptions each year. During 2024, though, one type of drug stood out—“wonder drugs” known as ...

Stocks were sharply higher in early-afternoon trading Friday, reversing earlier losses, as the market reacted to tame ...

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.

Patients taking the drugs eat less and they can experience side effects such as nausea, so they should prioritize certain ...

Novo Nordisk (NVO) released mixed clinical-trial results for its potential Ozempic successor on Friday, leaving Wall Street ...

Shares of Ozempic-maker Novo Nordisk were down more than 20% in recent trade as the Danish drugmaker headed for its worst day since the 1980s. The stock took a hit after a late-stage trial showed that ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...